85.04 0.00 (0.00%)
After hours: 4:57PM EDT
|Bid||84.55 x 1400|
|Ask||85.12 x 1200|
|Day's range||84.59 - 85.10|
|52-week range||66.10 - 87.35|
|Beta (3Y monthly)||0.32|
|PE ratio (TTM)||23.85|
|Earnings date||29 Oct 2019|
|Forward dividend & yield||2.20 (2.60%)|
|1y target est||96.36|
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, explains in a new interview why he decided to publicly resign from one of President Trump’s councils in the summer of 2017.
“Every person running for president has a plan to reduce pharmaceutical pricing,” Merck CEO Kenneth Frazier says. “Some of them I think are legitimate plans, some of them will hurt innovation, which we don’t want.”
Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
On Thursday, Kenneth Frazier, the CEO of pharmaceutical giant Merck (MRK), will kick off Yahoo Finance’s annual All Markets Summit in a keynote conversation
Merck (MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report. The report highlights the company’s performance and progress in its four corporate responsibility priority areas of Access to Health, Employees, Environmental Sustainability and Ethics & Values. “Operating responsibly is at the heart of our ability to deliver sustainable impact and long-term value for our business and society,” said Kenneth C. Frazier, Merck chairman and chief executive officer.
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China
Merck (MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental NDA (sNDA) for a new indication for use of DIFICID tablets and oral suspension for the treatment of Clostridium (also known as Clostridioides) difficile infections (CDI) in children aged six months or older. Both applications have received a priority review classification by the FDA.